Bio/Pharma Industry: Beyond Politics and the Pandemic

Video

Representatives of industry organizations discuss crucial business, regulatory, science-based issues facing the industry.

The bio/pharma industry has demonstrated its R&D capabilities by accelerating development of vaccines and therapeutics to combat COVID-19. At the same time the industry faced intense scrutiny and political pressure. What are the short-, medium-, and long-term implications for bio/pharma development and manufacturing?

Panelists James Mayne, PhD, vice-president, Science & Regulatory Advocacy, PhRMA and Phyllis Arthur, vice-president for infectious diseases and diagnostics policy, Biotechnology Innovation Organization (BIO) shared insights during this Editors’ Series discussion moderated by editors of Pharmaceutical Technology and BioPharm International. The discussion was recorded on Nov. 11, 2020, during the 2020 Bio/Pharma Virtual Congress.

Recent Videos
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

Feliza Mirasol
November 19th 2024
Article

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors

Feliza Mirasol
November 18th 2024
Article

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lecanemab Gets Nod from CHMP for Use in Early Alzheimer’s Disease

Felicity Thomas
November 15th 2024
Article

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Avantor Geared for Biopharma Industry’s Future with Next-Generation Biotherapeutics

Feliza Mirasol
November 14th 2024
Article

Avantor executives discuss the future of the biopharmaceutical industry and the impact that a wave of next-generation biotherapeutics will bring.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Collaboration between Merck and Ginkgo Bioworks for Improving Biologics Manufacturing Achieves First Milestone

Feliza Mirasol
November 12th 2024
Article

Ginkgo Bioworks has achieved the first milestone in an ongoing partnership with Merck, known as MSD outside of the United States and Canada, aimed at improving biologics production.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Manufacturers of Five Cell Therapy Products Select TrakCel’s OCELLOS Platform to Help Manage Patient Treatment

Feliza Mirasol
November 12th 2024
Article

TrakCel's OCELLOS, an IT platform, has been selected to orchestrate the administration of five out of seven autologous or matched allogenic cell therapy products approved or expected to be approved in 2024.

© 2024 MJH Life Sciences

All rights reserved.